FDA Avandia rules may driven by politics


If the stats on its clinical risks are so negative, why is diabetes drug Avandia still on the U.S. market? Well, according to blogger John Mack, a pharma industry insider who keeps a close eye on these things, the answer may have more to do with politics than medicine. As things stand, European regulators have […]

VN:F [1.9.7_1111]
Rating: +1 (from 1 vote)
Read the full article →